Evaluation of CD44 prognostic value in neuroblastoma: Comparison with the other prognostic factors
Authors:
- C. LassetCLC. Lasset
- D. FrappazDFD. Frappaz
- R. BouvierRBR. Bouvier
- P. ThiessePTP. Thiesse
- A.-C. RebillardARA.-C. Rebillard
- T. PhilipTPT. Philip
- M.C. FavrotMFM.C. Favrot
- 1 January 1995
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 31 (4) , 545-549
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Association between High Levels of Expression of the TRK Gene and Favorable Outcome in Human NeuroblastomaNew England Journal of Medicine, 1993
- Indication and limits of megatherapy and bone marrow transplantation in high-risk neuroblastoma: A single centre analysis of prognostic factorsEuropean Journal of Cancer, 1993
- Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein.Journal of Experimental Medicine, 1992
- Expression of integrin receptors on 45 clinical neuroblastoma specimensInternational Journal of Cancer, 1991
- Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition.Journal of Experimental Medicine, 1990
- CD44 is the principal cell surface receptor for hyaluronateCell, 1990
- Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocolsEuropean Journal of Cancer and Clinical Oncology, 1989
- Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types.Journal of Cell Biology, 1989
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958